WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406325

CAS#: 593960-11-3

Description: PIK-93 is a potent PI3K inhibitor. PIK93 selectively inhibits the type III PI 4-kinase beta enzyme, and small interfering RNA-mediated down-regulation of the individual PI 4-kinase enzymes, revealed that PI 4-kinase beta has a dominant role in ceramide transport between the ER and Golgi.

Price and Availability


USD 240

USD 610

PIK93 purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 406325
Name: PIK-93
CAS#: 593960-11-3
Chemical Formula: C14H16ClN3O4S2
Exact Mass: 389.02708
Molecular Weight: 389.88
Elemental Analysis: C, 43.13; H, 4.14; Cl, 9.09; N, 10.78; O, 16.41; S, 16.45

Synonym: PIK93; PIK 93; PIK-93.

IUPAC/Chemical Name: N-(5-(4-chloro-3-(N-(2-hydroxyethyl)sulfamoyl)phenyl)-4-methylthiazol-2-yl)acetamide


InChi Code: InChI=1S/C14H16ClN3O4S2/c1-8-13(23-14(17-8)18-9(2)20)10-3-4-11(15)12(7-10)24(21,22)16-5-6-19/h3-4,7,16,19H,5-6H2,1-2H3,(H,17,18,20)

SMILES Code: CC(NC1=NC(C)=C(C2=CC=C(Cl)C(S(=O)(NCCO)=O)=C2)S1)=O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition:
0– 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).

soluble in DMSO

Shelf Life:
>2 years if stored properly.

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1. Inhibitors of the PI3k/Akt/Ikk/NF-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for prophylaxis and treatment of viral diseases. By Fedichev, Petr Olegovich; Vinnik, Andrey Alexandrovich. From PCT Int. Appl. (2013), WO 2013147649 A2 20131003,

2. Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo. By Spickler, Catherine; Lippens, Julie; Laberge, Marie-Kristine; Desmeules, Sophie; Bellavance, Edith; Garneau, Michel; Guo, Tim; Hucke, Oliver; Leyssen, Pieter; Neyts, Johan; et al. From Antimicrobial Agents and Chemotherapy (2013), 57(7), 3358-3368. ,

3. Autoimmune and inflammatory disorder therapy using inhibitors of phosphatidylinositol-4-kinase IIIβ and screening methods thereof By Herman, Jean; Louat, Thierry; Huang, Qiuya; Vanderhoydonck, Bart; Waer, Mark; Herdewijn, Piet From PCT Int. Appl. (2013), WO 2013034738 A1 20130314,

4. Methods for predicting cancer treatment responsiveness to phosphatidylinositol 3-kinase (PI3K) inhibitors. By Jane, Stephen M.; Darido, Charbel. From PCT Int. Appl. (2013), WO 2013029116 A1 20130307,

5. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. By van der Schaar, Hilde M.; van der Linden, Lonneke; Lanke, Kjerstin H. W.; Strating, Jeroen R. P. M.; Puerstinger, Gerhard; de Vries, Erik; de Haan, Cornelis A. M.; Neyts, Johan; van Kuppeveld, Frank J. M. From Cell Research (2012), 22(11), 1576-1592. , DOI:10.1038/cr.2012.129

6. Methods for treating oncovirus positive cancers. By Jimeno, Antonio; Hausman, Diana F.; Peterson, Scott. From PCT Int. Appl. (2012), WO 2012118978 A1 20120907,

7. Methods and compositions targeting signaling pathways for the treatment of cancer By Brugge, Joan S.; Muranen, Taru; Mills, Gordon; Selfors, Laura. From PCT Int. Appl. (2011), WO 2011133668 A2 20111027,

8. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity By Arita, Minetaro; Kojima, Hirotatsu; Nagano, Tetsuo; Okabe, Takayoshi; Wakita, Takaji; Shimizu, Hiroyuki. From Journal of Virology (2011), 85(5), 2364-2372. , DOI:10.1128/JVI.02249-10

9. Modification of proteins for detection in cellular assays By Treiber, Daniel Kelly; Lewis, Warren G.; Wodicka, Lisa M. From PCT Int. Appl. (2010), WO 2010124157 A1 20101028,

10. Shaping Development of Autophagy Inhibitors with the Structure of the Lipid Kinase Vps34 By Miller, Simon; Tavshanjian, Brandon; Oleksy, Arkadiusz; Perisic, Olga; Houseman, Benjamin T.; Shokat, Kevan M.; Williams, Roger L. From Science (Washington, DC, United States) (2010), 327(5973), 1638-1642. ,

11. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110α By Zunder, Eli R.; Knight, Zachary A.; Houseman, Benjamin T.; Apsel, Beth; Shokat, Kevan M. From Cancer Cell (2008), 14(2), 180-192. , DOI:10.1016/j.ccr.2008.06.014

12. Phosphoinositide modulation for the treatment of neurodegenerative diseases By Kim, Tae-Wan; Dipaolo, Gilbert; Kang, Min Suk; Berman, Diego; McIntire, Laura Beth Johnson From PCT Int. Appl. (2008), WO 2008064244 A2 20080529,

13. Design of Drug-Resistant Alleles of Type-III Phosphatidylinositol 4-Kinases Using Mutagenesis and Molecular Modeling By Balla, Andras; Tuymetova, Galina; Toth, Balazs; Szentpetery, Zsofia; Zhao, Xiaohang; Knight, Zachary A.; Shokat, Kevan; Steinbach, Peter J.; Balla, Tamas From Biochemistry (2008), 47(6), 1599-1607. , DOI:10.1021/bi7017927

14. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling By Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; et al From Cell (Cambridge, MA, United States) (2006), 125(4), 733-747. ,

15. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma . By Fan, Qi-Wen; Knight, Zachary A.; Goldenberg, David D.; Yu, Wei; Mostov, Keith E.; Stokoe, David; Shokat, Kevan M.; Weiss, William A. From Cancer Cell (2006), 9(5), 341-349.

16. 5-Phenylthiazole derivatives and their use as phosphatidylinositol 3-kinase (Pi3K) inhibitors for the treatment of allergic and inflammatory diseases. By Bruce, Ian; Finan, Peter; Leblanc, Catherine; McCarthy, Clive; Whitehead, Lewis; Blair, Nicola Elaine; Bloomfield, Graham Charles; Hayler, Judy; Kirman, Louise; Oza, Mrinalini Sachin; et al. From PCT Int. Appl. (2003), WO 2003072557 A1 20030904,